🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to scientists.

An International Public Health Issue

Gonorrhoea infections are escalating around the world, with data suggesting in excess of 82 million infections each year. Particularly high rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the face of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Receive Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This approval marks a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on data detailed in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which uses two antibiotics. The trial included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Medical professionals directly involved have expressed optimism. The availability of a easy-to-administer therapy like this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for people and to stop the proliferation of untreatable gonorrhoea worldwide.